The National Institutes of Health (NIH) grant was made under the National Institute for Allergy and Infectious Disease (NIAID) program entitled “cooperative research for the development of vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics for biodefense and SARS.”
“This support extends our partnership with the NIH in striving to meet the critical needs for protection against influenza,” said Stanley Erck, president and CEO of Iomai Corporation. “Iomai patch technology has the potential to stimulate stronger responses to both annual flu vaccines, especially in the elderly, and to vaccines developed to combat new, or pandemic, outbreaks of influenza.”
Iomai Corporation has pioneered the delivery of vaccines to the skin through a proprietary technology known as transcutaneous immunization, or TCI. The company is evaluating skin immunization techniques in several human clinical trials, including those to prevent influenza in the healthy adult and elderly populations, and also to prevent travelers’ diarrhea and anthrax.